Megna Michael R
CHIEF ACCOUNTING OFFICER
Megna Michael R has filed 9 SEC Form 4 filings (43 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.
On the most recent filing, Megna Michael R is listed as CHIEF ACCOUNTING OFFICER at Kiniksa Pharmaceuticals International, plc. Inside the rolling window, Megna Michael R reported no open-market purchases and 4 open-market sales totaling $5.2M in KNSA. The largest disclosed transaction in the window is a sale of 36,260 KNSA shares on Oct 30, 2026, worth $3.4M.
Companies traded
Other insiders at KNSA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Megna Michael R made?
Megna Michael R has filed 9 SEC Form 4 filings (43 transaction rows) across 1 company since 2025.
Which companies does Megna Michael R trade?
Megna Michael R has filed SEC Form 4 disclosures for 1 company, including KNSA.
When was Megna Michael R's most recent SEC Form 4 filing?
Megna Michael R's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.
What is Megna Michael R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Megna Michael R is listed as CHIEF ACCOUNTING OFFICER.
What is Megna Michael R's total buy and sell value in the current window?
Inside the rolling retention window, Megna Michael R bought $0 and sold $5.2M based on SEC Form 4 filings.
What was Megna Michael R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 36,260 KNSA shares on 2026-10-30, worth $3.4M, per SEC Form 4 filings.